Tyra Biosciences, Inc. (TYRA): Results of Operations and Financial Condition
Tyra Biosciences, Inc. (TYRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights - Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) - - Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including
How this was made
The 30-second read
Why it matters
The most tradable new information is the updated clinical-data timeline for SURF302 (September 2026) and BEACH301 (end of Q1 2027), alongside cash runway into 2H 2028 and an amended ATM that increases potential share issuance.
Market read
Traders can position around the next disclosed clinical catalyst (SURF302 initial data in September 2026) while monitoring dilution overhang from the expanded ATM capacity and ongoing burn-rate signals.
What to watch
R&D expense rose sharply year over year, and the filing does not provide efficacy results yet, so the market may still discount until SURF302 safety and efficacy are actually reported.
Background
This is an SEC Form 8-K (Item 2.02) with Q2 2026 financial results and corporate updates for Tyra Biosciences’ FGFR3-targeted oral dabogratinib program.
Ticker impact
Tyra reported Q2 2026 results and said initial Phase 2 SURF302 data for oral dabogratinib is expected in September 2026.
Moderate upside bias into the September data window, with volatility around trial updates and cash runway commentary.
The filing adds concrete timing for upcoming clinical readouts (SURF302 in September 2026, BEACH301 end of Q1 2027) plus cash runway into 2H 2028, which can re-rate risk and expectations for FGFR3-driven indications.
Market effects
Reinforces investor focus on FGFR3-targeted, oral oncology therapies and the market’s appetite for near-term Phase 2 readouts in rare/oncology indications.
Limited direct regional spillover; primarily affects US biotech sentiment and clinical-trial risk appetite.
Global relevance is mainly through the universal bladder cancer and achondroplasia treatment narratives, not through a cross-border commercial event.
Counterpoint
Cash runway and pipeline progress may not offset dilution risk from the amended ATM sales agreement, which can cap upside even with positive trial momentum.
Key entities
- companyTyra Biosciences, Inc.
Clinical-stage biotech developing oral dabogratinib targeting FGFR3 biology; reported Q2 2026 results and provided upcoming Phase 2 readout timing.
- product_candidatedabogratinib
Orally available FGFR3-selective inhibitor being studied across SURF302 (IR NMIBC), SURF303 (LG-UTUC), and BEACH301 (achondroplasia).
- clinical_programSURF302
Phase 2 study in FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer; initial data expected in September 2026.
- clinical_programBEACH301
Phase 2 study in achondroplasia; fifth dose level opened and initial safety sentinel cohort results expected end of Q1 2027.
- counterpartyTD Securities (USA) LLC
Counterparty to the amended ATM sales agreement enabling additional share sales up to $250 million.
